ALK2 inhibitor

ALK2 inhibitors are a class of small molecule therapeutics that target the Activin A receptor type 1 (ACVR1), also known as ALK2. This receptor is a type I bone morphogenetic protein (BMP) receptor that, upon activation, phosphorylates SMAD1/5/8 proteins to regulate gene expression involved in cell growth, differentiation, and bone formation. Gain-of-function mutations in ACVR1 are the primary drivers of Fibrodysplasia Ossificans Progressiva (FOP) and are found in approximately 25% of pediatric diffuse midline gliomas (DMG), H3K27-altered. ALK2 inhibitors are designed to bind to the intracellular kinase domain of the receptor, blocking its signaling activity. In the context of DMG, research has demonstrated that ALK2 inhibition can be potentiated by combining it with agents that target cholesterol metabolism, such as statins or LXR agonists, to exploit metabolic vulnerabilities in tumor cells.